在急性心肌梗死患者急性期应用依洛尤单抗降脂治疗效果研究  

Study on the Efficacy of Lipid-lowering Therapy with Evolocumab during the Acute Phase in Patients with Acute Myocardial Infarction

作　　者：陈文中 温晓莉 薛红红 CHEN Wenzhong;WEN Xiaoli;XUE Honghong(Department of Cardiology,The Third People's Hospital of Huizhou,Huizhou 516000,Guangdong,China)

机构地区：[1]惠州市第三人民医院心内科,广东惠州516000

出　　处：《系统医学》2024年第24期124-127,共4页Systems Medicine

基　　金：惠州市科技计划项目(2022CZ010245)。

摘　　要：目的 分析依洛尤单抗对急性ST段抬高型心肌梗死(ST segment elevation myocardial infarction, STEMI)患者经皮冠状动脉介入术(percutaneous coronary intervention, PCI)术后血脂的影响。方法 非随机选取2023年1月—2024年9月惠州市第三人民医院收治的120例行PCI治疗的急性STEMI患者为研究对象,根据治疗方式不同分为两组,每组60例,对照组行常规治疗,观察组在对照组的基础上加用依洛尤单抗,对比两组的血脂水平、主要不良心血管事件、不良反应。结果 观察组的血脂水平优于对照组,差异有统计学意义(P均<0.05)。观察组的主要不良心血管事件发生率为3.33%(2/60),低于对照组的13.33%(8/60),差异有统计学意义(χ^(2)=3.927,P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论 依洛尤单抗可以改善急性STEMI患者PCI术后血脂水平,同时可以降低不良心血管事件发生风险,安全性良好。Objective To investigate the effect of ilozumab on blood lipid in patients with acute ST segment elevation myocardial infarction(STEMI)after percutaneous coronary intervention(PCI).Methods 120 acute STEMI patients treated by PCI in The Third People's Hospital of Huizhou from January 2023 to September 2024 were non-randomly selected as the study objects,and were divided into two groups according to different treatment methods.There were 60 cases in each group.The control group received routine treatment,and the observation group received ilozumab on the basis of the control group.Blood lipid levels,major adverse cardiovascular events and adverse reactions were com‐pared between the two groups.Results The blood lipid levels of the observation group were better than those of the control group,and the differences were statistically significant(all P<0.05).The incidence of major adverse cardiovas‐cular events was 3.33%(2/60)in the observation group,lower than 13.33%(8/60)in the control group,the difference was statistically significant(χ^(2)=3.927,P<0.05).There was no significant difference in the incidence of adverse reac‐tions between the two groups(P>0.05).Conclusion Evolocumab can improve blood lipid levels in acute STEMI pa‐tients after PCI and reduce the risk of adverse cardiovascular events with good safety.

关 键 词：依洛尤单抗 急性ST段抬高型心肌梗死 血脂 不良反应 

分 类 号：R542[医药卫生—心血管疾病]